Nasdaq Stocks
Primoris Services (PRIM) Sees Hammer Chart Pattern: Time to Buy?
Groupon (GRPN) Sees Hammer Chart Pattern: Time to Buy?
5 Best Stocks With Rising P/E to Buy for Solid Returns
Schnitzer Steel (SCHN) to Post Q2 Earnings: What's in the Cards?
Here's Why You Should Add Celanese (CE) to Your Portfolio
S&P 500 Hits 4K Milestone on Fabulous Economic Data: 5 Picks
POLL-Half of Republicans believe false accounts of deadly U.S. Capitol riot-Reuters/Ipsos poll
Turtle Beach Extends Share BuyBack Program To $25 Million; Street Is Bullish
The Turtle Beach Corporation has extended its share repurchase program to $25 million. The gaming accessory maker initially approved a buyback program of $15 million in April 2019. Shares of Turtle Beach closed 2.9% higher on Thursday.
Turtle Beach (HEAR) said that it will continue to repurchase shares over the next two years under the expanded buyback program. The program will expire on April 9, 2023.
The company’s CEO Juergen Stark said, “Our strong position in console gaming headsets, rapid growth in PC accessories, and planned entry into additional new gaming accessory categories give us continued confidence in our ability to grow and generate strong financial results.”
Stark added, “The consistently high levels of free cash flow we have generated in recent years allowed us to eliminate our debt and end 2020 with high levels of cash. This, in turn, allows us to continue executing our proven strategy while remaining committed to investing in profitable growth.” (See Turtle Beach stock analysis on TipRanks)
On March 4, Turtle Beach reported upbeat 4Q results, wherein earnings of $0.93 per share topped analysts’ estimates of $0.78, while revenues of $132.9 million beat the consensus estimate of $131.4 million.
Following the results, Maxim Group analyst Jack Vander Aarde maintained a Buy rating and a price target of $42 (53.1% upside potential). In a note to investors, the analyst said, “We believe HEAR's data-driven approach to managing the business positions the company well to take additional share of the growing $2.7B+ console headset market (note, HEAR had 46.8% market share in 2020), and successfully expand into the $2.8B+ PC headset and accessories market, as well as the ~$2.3B global microphone market.” Aarde added that the valuation remains compelling.
Overall, the Street has a Strong Buy consensus rating on the stock based on 5 unanimous Buys. The average analyst price target of $40 implies upside potential of about 45.8% to current levels. Shares have skyrocketed by about 339.6% in one year.
On TipRanks’ Smart Score ranking, Turtle Beach gets an 8 out of 10 suggesting that the stock is likely to outperform market expectations.
Related News:
Macerich Sells Paradise Valley Mall For $100M
Resideo Technologies Gains 5% On Norfolk Acquisition
Tesla Tops Expectations, Delivers Record Vehicles In 1Q
Macerich Sells Paradise Valley Mall For $100M
Macerich announced that it has sold its Paradise Valley Mall, a non-core shopping center asset in Phoenix for $100 million to a joint venture between RED Development and its affiliates. The company added that it finalized the transaction on March 29.
Macerich’s (MAC) Paradise Valley Mall is a 92-acre site that the newly formed joint venture intends to convert into a community of multi-family residences, offices, high-end grocery, restaurants, and retail shops.
The US mall owner revealed that it has retained 5% interest in the newly formed joint venture. The transaction has generated net proceeds of $95 million to the real estate investment trust (REIT) company.
As per the terms of the joint venture deal, the site will cover approximately 6.5 million square feet of building area. Of the total, approximately 3.25 million square feet area will be used for residential space and the remaining 3.25 million square feet for non-residential purposes such as retail shops, restaurants and offices. (See Macerich stock analysis on TipRanks)
Macerich President Ed Coppola said, "As the retail landscape continues to evolve here in Arizona and around the country, our decision to realize the market value of this non-core asset makes sense for Macerich." He further added "Our focus remains on Macerich's top-tier, market-dominant properties that will continue to benefit from the industry's increasing momentum toward high-quality destinations."
On March 22, Truist Financial analyst Ki Bin Kim raised the stock’s price target to $15 (25.3% upside potential) from $14 and reiterated a Hold rating. Kim’s upbeat price target for Macerich is a part of his broader research on REITs. The analyst raised his estimates based on the industry’s latest quarterly performance along with recent events, revenue growth and expenses assumptions.
Overall, the rest of the Street has a Moderate Sell consensus rating based on 1 Hold and 1 Sell. The average analyst price target of $13.25 implies upside potential of about 10.7% to current levels. Shares have gained about 114.9% in one year.
Related News:
Bausch Health Sells Amoun Pharmaceuticals For $740 Million
Aytu BioPharma Sells U.S. Rights For Natesto To Acerus Pharma; Street Sees 131.5% Upside
Franklin Electric Snaps Up Puronics
Emergent Receives $23M From BARDA To Support Johnson & Johnson Vaccine Ramp Up
Life sciences company Emergent BioSolutions Inc. has received a $23 million contract modification from Biomedical Advanced Research and Development Authority (BARDA). The company is on track with its COVID-19 vaccine manufacturing agreements and plans to use the $23 million to acquire biologics manufacturing equipment specific to Johnson & Johnson’s COVID-19 vaccine.
Emergent BioSolutions (EBS) President and Chief Executive Officer, Robert G. Kramer, said, “Emergent is actively working with the U.S. government to fulfil its policy objectives consistent with the Center for Innovation in Advanced Development and Manufacturing (CIADM) that was put in place under the Obama-Biden Administration in 2012.”
Kramer added, “This unique public-private partnership has been a key element in our ability to quickly scale up to produce COVID-19 vaccines at a current rate of more than one billion dose-equivalents annually. Emergent’s top priority continues to be the strengthening of the supply chain for Johnson & Johnson’s vitally needed COVID-19 vaccine.” (See Emergent BioSolutions stock analysis on TipRanks)
Additionally, Emergent also plans to decrease the manufacturing of AstraZeneca’s COVID-19 vaccine bulk drug substance. This decrease is in-line with a mutual agreement of the company with the U.S. government and AstraZeneca.
Currently, Emergent has nine COVID-19 CDMO partnerships with the U.S. government, pharmaceutical and biotech companies as well as non-government organizations.
Recently, Chardan Capital analyst Keay Nakae upgraded the stock to Buy from Hold and maintained a $112 price target.
Nakae said, “2020 was a great year for Emergent. The Company’s CDMO business was a significant beneficiary of the Covid-19 pandemic, and Management did an excellent job to leverage their vaccine manufacturing capacity to capture numerous large contracts. The bulk of these agreements are ‘take or pay’ arrangements under which Emergent is being paid to reserve manufacturing capacity for these various SARS-CoV-2 vaccine initiatives.”
Turning to the rest of the Street, the stock has a Moderate Buy consensus rating alongside an average analyst price target of $118 (46.7% upside potential), based on 2 Buys and 1 Hold. Shares have gained about 48.1% over the past year.
Related News:
12 Technology Stocks Worth Watching
Abbott’s BinaxNOW COVID-19 Ag Self Test Cleared For Emergency Use In US
Acuity Brands Pops 13% After 2Q Earnings Beat, Sales Disappoint
Vipshop To Buy Back $500M In Stock; Shares Pop 9%
POLL-Turkish inflation to jump above 16% after lira decline
Best Tech Stocks To Watch This Week? 4 Names To Know
Top Dividend Stocks To Buy In 2021? 5 For Your List
S&P 500 Tops 4000: What This Means for the Market
Mitek: A Promising Name Held Back By Legal Troubles
The market for digital identity verification is expected to grow at a pace of over 13% CAGR for the next several years. Mobile identity verification is set to grow even faster.
Among the names vying for a share of the market is Mitek Systems, Inc. (MITK), a company known primarily for its remote check deposit service called Mobile Deposit. Mitek's application, which utilizes the user's mobile or PC camera to scan checks as well as verify the identity of the user, allows checks to be deposited remotely at more than 7,500 financial institutions.
The pandemic has been a significant tailwind for Mitek's remote check deposit business, but there are two lingering problems that have suppressed the share price. The first is that the market for remote check deposit is fading as fast as the use of checks. It may take several years, but the use of checks will eventually disappear almost entirely, replaced by various forms of digital payments.
As for the second, it relates to an ongoing patent dispute with former partner and now competitor United Services Automobile Association (USAA).
Legal Troubles
Several years ago, the two companies teamed up to develop a remote check deposit solution, but in 2012, they had a falling out over patent ownership. In 2014, the differences were settled and both companies agreed to suspend legal actions.
Now, after several years and a change in leadership, USAA has picked its patent infringement accusations back up. However, USAA has a new strategy. It is not suing Mitek, but instead is taking legal action against Mitek's customers. USAA has already won two judgements against Wells Fargo (WFC) in excess of $300 million combined. Additionally, USAA has now announced that it is going after PNC Bank. If USAA keeps winning in court, it could theoretically take legal action against each of Mitek's 7,500 customers.
While the final outcome of the dispute between USAA and Mitek is uncertain, USAA has been victorious in court so far against Wells Fargo. Wells Fargo has not been successful in reversing the court decisions and has not indicated whether it would attempt to recover the settlement from Mitek, which would likely bankrupt the latter.
Identity-as-a-Service
Currently, two-thirds of Mitek's revenue comes from remote check deposits. Given the two problems with remote check deposit highlighted above, it is important for Mitek to expand into new industries.
The company has been doing just that the last few years by venturing into the Identity-as-a-Service (IDaaS) space. The purpose of IDaaS is to verify an individual's identity during digital transactions. Given that Mitek already has a relationship with a vast number of retail banks and other financial institutions, this should prove to be an advantage for growing the company's IDaaS market share.
Its applications include Mobile Verify and Mobile Docs. Mobile Verify provides customers with the means to scan an identity card or passport, verify the customer's identify with live face comparison, and pre-fill forms with the extracted information. Mobile Docs allows users to upload documents while verifying the owner and the owner's address. The application is used for such services as brokerage account opening, remote notarization, remote hotel check-in, and accessing government websites.
Putting the legal issues aside, Mitek has been a strong performer, particularly during the pandemic when remote deposit has had a renaissance of sorts with the distribution of government handouts. In Q1'21, total revenue grew by 18% year-over-year. Identity Verification revenue grew by an impressive 40% year-over-year. On top of this, trailing twelve-month free cash flow margin of 25% was also very strong. Despite the solid financial performance, the stock price is a bargain, with a price/sales ratio of 6, quite low for a growth stock.
Wall Street’s Take
From Wall Street analysts, Mitek earns a Strong Buy consensus rating, based on 3 unanimous Buys. Additionally, the average analyst price target of $22.00 puts the upside potential at 44%. (See Mitek Systems stock analysis on TipRanks)
Summary And Conclusions
Mitek is an industry leader in remote check deposit, an industry that experienced strong tailwinds during the pandemic. That said, the company faces two problems. First and foremost, the market for remote deposit is expected to shrink over the next several years in conjunction with declining check usage. The second issue is that Mitek has an ongoing patent dispute with USAA, and depending on how the court actions play out with Mitek's customers, the company could end up bankrupt.
On the positive side, Mitek has more than 7,500 customers consisting of regional banks and other financial institutions. Mitek's relationship with these organizations is ideal for cultivating the company's IDaaS applications. Revenue growth and free cash flow are also both strong.
Disclosure: On the date of publication, Steve Auger did not have (either directly or indirectly) any positions in the securities mentioned in this article.
Disclaimer: The information contained herein is for informational purposes only. Nothing in this article should be taken as a solicitation to purchase or sell securities.
Global Blood Therapeutics: Can This Biotech Still Disrupt The Sickle Cell Disease Space?
Global Blood Therapeutics (GBT) burst onto the biotech scene with a novel oral treatment for Sickle cell disease (SCD). GBT's lead product, dubbed Oxbryta (Voxelotor), received US FDA clearance in November of 2019, ushering in a new treatment paradigm for SCD.
Oxbryta was designed to reduce the amount of misshapen or otherwise crescent-shaped red blood cells in the patient's body. In SCD, the misshapen cells can create a blockage (vaso-occlusive crises) in the patient's veins, leading to a stroke and organ damage. The abnormal cells also lose their binding capacity for hemoglobin, depriving the patient of adequate oxygen, saddling the patient with chronic fatigue.
The therapy helps tackle the disorder at its root by inhibiting the process of deoxygenated sickle-hemoglobin polymerization. By preventing the cells from becoming misshaped, the therapy's goal is to reduce the side effect profile of patients while simultaneously improving the quality of life. SCD reduces the average lifespan of a patient by thirty years as the effects of the disease begin to manifest themselves at a young age.
It should also be noted that Oxbryta therapy is relatively straight-forward, with the recommended dose of three capsules (500mg each) taken once a day with or without food.
Commercial Progress
Oxbryta seemed poised for rapid commercial success, with a clear path to sustained growth. However, just when GBT began to ramp up its marketing efforts, COVID-19 placed unforeseen burdens on its progress.
The SCD patient population is considered high-risk for contraction of COVID-19, which dampened initial uptake. Practitioners are often reluctant to change therapies to a newer, commercially untested product as they want to ensure that patients do not suffer adverse effects.
To this end, the impact of the pandemic has hampered prescription growth, with Q3 2020 quarterly numbers underwhelming investors. One of the culprits was slower patient uptake, with roughly 1,000 new patients added in Q3. Q4 2020 numbers were also lackluster as the winter months led to more caution on the part of the patient population when it came to seeking new treatment options.
As such, the multi-quarter disappointments hurt the share price, with the security trading at levels last seen in December of 2018 before Oxbryta was approved. The optimistic case is uptake will accelerate significantly once mass vaccination takes place throughout the US in the next few months.
In this case, patients will likely be more open to receiving a new treatment, with the estimated value of the SCD market in the US pegged at $5 billion. Therefore, GBT seems poised to capture a large amount of the market.
Potential Challenges Holding The Company Back
Healthcare is often never as clear-cut as it seems. Based on the ease of use and the easy to understand mechanism of action of Oxbryta, GBT seems well-positioned. However, over the last three years, shares have declined 7%.
The delay in uptake has cost GBT precious time to cement its position in the market. What’s more, there could be additional disruption, assuming the FDA is open-minded with gene-therapy. Sangamo (SGMO) and Sanofi (SNY) have joined forces to develop a potential gene therapy for SCD, which, if approved, could potentially offer a one-time cure for the genetic abnormality.
Interestingly, SNY has entered into an agreement with GBT, which will see GBT investigate SNY's two early-stage programs, with one compound providing a promising anti-sickling mechanism and the other reducing inflammation and oxidative stress. The partnership may serve as an initial step towards a takeover as the management teams get to know each other, the corporate culture, and the strength of the scientific backbone of GBT.
Analysts Weigh In
Looking at the consensus breakdown, 7 Buys and 4 Holds have been assigned in the last three months. At $78.38, the average analyst price target puts the upside potential at 84%. (See Global Blood Therapeutics stock analysis on TipRanks)
Concluding Thoughts
GBT has some exciting technology, with the potential to grab a large share of the SCD market. That said, the pandemic has hampered initial uptake, which may shorten the time GBT has to establish its dominance before other gene-therapy players can potentially disrupt it.
Disclosure: Alexander Poulos held no position in any of the stocks mentioned in this article at the time of publication.
Disclaimer: The information contained herein is for informational purposes only. Nothing in this article should be taken as a solicitation to purchase or sell securities.